Literature DB >> 16216855

Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy.

P M Elliott1, J R Gimeno, R Thaman, J Shah, D Ward, S Dickie, M T Tome Esteban, W J McKenna.   

Abstract

OBJECTIVE: To determine the range of survival rates of patients with hypertrophic cardiomyopathy (HCM) by comparing and contrasting the natural history of a cohort of patients seen between 1988 and 2002 with that of other published series.
METHODS: 956 adult (> or = 16 years old) patients with HCM (572 men, mean (SD) age 42 (15) years, range 16-88) were evaluated by ECG, Holter, exercise testing, and echocardiography. Patient characteristics and survival data were compared with those in natural history studies from referral and non-referral centres published between 1960 and January 2003.
RESULTS: The duration of follow up was 69 (45) months. 120 (12.6%) patients died or underwent cardiac transplantation. Sudden cardiac death (n = 48) was the most common mode of death. The annual rate of sudden death or implantable cardioverter-defibrillator discharge was 1.02 (95% confidence interval (CI) 0.76 to 1.26). Annual rates for heart failure death or transplantation and stroke related death were 0.55% (95% CI 0.37% to 0.78%) and 0.07% (95% CI 0.02% to 0.19%), respectively. When studies published within the last 10 years of the study period were compared with earlier reports, the size of individual study cohorts was larger (309 (240.6) v 136.5 (98.8), p = 0.058) and the proportion with severe functional limitation NYHA class III/IV lower (12.4% v 24.8%, p < 0.0001), and fewer patients underwent septal myotomy-myectomy (5.2% v 18.7%, p < 0.0001). Published sudden death rates over the last 10 years were lower than previously published figures (median 1.0% (range 0.1-1.7) v 2.0% (0-3.5)).
CONCLUSION: Published survival rates in HCM cohorts have improved progressively over the past 40 years. In the modern era the prevalence of disease related complications is similar in all reporting centres.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16216855      PMCID: PMC1860645          DOI: 10.1136/hrt.2005.068577

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  35 in total

1.  Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy.

Authors:  P M Elliott; J R Gimeno Blanes; N G Mahon; J D Poloniecki; W J McKenna
Journal:  Lancet       Date:  2001-02-10       Impact factor: 79.321

Review 2.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines.

Authors:  Barry J Maron; William J McKenna; Gordon K Danielson; Lukas J Kappenberger; Horst J Kuhn; Christine E Seidman; Pravin M Shah; William H Spencer; Paolo Spirito; Folkert J Ten Cate; E Douglas Wigle
Journal:  J Am Coll Cardiol       Date:  2003-11-05       Impact factor: 24.094

3.  IDIOPATHIC HYPERTROPHIC SUBAORTIC STENOSIS. I. A DESCRIPTION OF THE DISEASE BASED UPON AN ANALYSIS OF 64 PATIENTS.

Authors:  E BRAUNWALD; C T LAMBREW; S D ROCKOFF; J ROSS; A G MORROW
Journal:  Circulation       Date:  1964-11       Impact factor: 29.690

4.  Prognosis and mortality of hypertrophic obstructive cardiomyopathy.

Authors:  T Hardarson; C S De la Calzada; R Curiel; J F Goodwin
Journal:  Lancet       Date:  1973-12-29       Impact factor: 79.321

5.  The natural (and unnatural) history of hypertrophic obstructive cardiomyopathy.

Authors:  P M Shah; A G Adelman; E D Wigle; F L Gobel; H B Burchell; T Hardarson; R Curiel; C De La Calzada; C M Oakley; J F Goodwin
Journal:  Circ Res       Date:  1974-08       Impact factor: 17.367

6.  Sudden death in hypertrophic cardiomyopathy: identification of high risk patients.

Authors:  P M Elliott; J Poloniecki; S Dickie; S Sharma; L Monserrat; A Varnava; N G Mahon; W J McKenna
Journal:  J Am Coll Cardiol       Date:  2000-12       Impact factor: 24.094

7.  Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations.

Authors:  Jens Mogensen; Toru Kubo; Mauricio Duque; William Uribe; Anthony Shaw; Ross Murphy; Juan R Gimeno; Perry Elliott; William J McKenna
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

8.  [A study of the natural evolution of hypertrophic obstructive cardiomyopathy. Analysis of 100 cases (authors' transl)].

Authors:  V Ceci; F Milazzotto; V Masini
Journal:  G Ital Cardiol       Date:  1978

9.  "Malignant" hypertrophic cardiomyopathy: identification of a subgroup of families with unusually frequent premature death.

Authors:  B J Maron; L C Lipson; W C Roberts; D D Savage; S E Epstein
Journal:  Am J Cardiol       Date:  1978-06       Impact factor: 2.778

10.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy.

Authors:  P Spirito; P Bellone; K M Harris; P Bernabo; P Bruzzi; B J Maron
Journal:  N Engl J Med       Date:  2000-06-15       Impact factor: 91.245

View more
  62 in total

Review 1.  Chromosomal regulation by MeCP2: structural and enzymatic considerations.

Authors:  N J Bowen; M B Palmer; P A Wade
Journal:  Cell Mol Life Sci       Date:  2004-09       Impact factor: 9.261

2.  MRI T1 Mapping in Hypertrophic Cardiomyopathy: Evaluation in Patients Without Late Gadolinium Enhancement and Hemodynamic Obstruction.

Authors:  Jing Xu; Baiyan Zhuang; Arlene Sirajuddin; Shuang Li; Jinghan Huang; Gang Yin; Lei Song; Yong Jiang; Shihua Zhao; Minjie Lu
Journal:  Radiology       Date:  2019-11-26       Impact factor: 11.105

Review 3.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

4.  Mutations in NEXN, a Z-disc gene, are associated with hypertrophic cardiomyopathy.

Authors:  Hu Wang; Zhaohui Li; Jizheng Wang; Kai Sun; Qiqiong Cui; Lei Song; Yubao Zou; Xiaojian Wang; Xuan Liu; Rutai Hui; Yuxin Fan
Journal:  Am J Hum Genet       Date:  2010-10-21       Impact factor: 11.025

5.  Heart rate variability is a weak predictor of sudden death in children and young patients with hypertrophic cardiomyopathy.

Authors:  G Limongelli; T Miele; G Pacileo; G Di Salvo; P Calabro'; R Ancona; S Gala; A Rea; M Verrengia; R Calabro'
Journal:  Heart       Date:  2007-01       Impact factor: 5.994

Review 6.  [Primary and secondary prophylactic ICD therapy in congenital electrical and structural cardiomyopathies].

Authors:  D Duncker; T König; S Hohmann; C Veltmann
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2015-05-22

Review 7.  Sudden cardiac death in patients with nonischemic cardiomyopathy.

Authors:  Brian P Betensky; Sanjay Dixit
Journal:  Indian Heart J       Date:  2014-01-06

8.  Impact of QT variables on clinical outcome of genotyped hypertrophic cardiomyopathy.

Authors:  Katsuharu Uchiyama; Kenshi Hayashi; Noboru Fujino; Tetsuo Konno; Yuichiro Sakamoto; Kenji Sakata; Masa-aki Kawashiri; Hidekazu Ino; Masakazu Yamagishi
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-01       Impact factor: 1.468

9.  Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: Dutch cardiologists and the care of mutation carriers.

Authors:  J T Vehmeijer; I Christiaans; I M van Langen; E Birnie; G J Bonsel; E M A Smets; A A M Wilde
Journal:  Neth Heart J       Date:  2009-12       Impact factor: 2.380

Review 10.  Genetic determinants of cardiac hypertrophy.

Authors:  Ali J Marian
Journal:  Curr Opin Cardiol       Date:  2008-05       Impact factor: 2.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.